RxDoctor Payments Data

Joseph Abreu, MD

Cardiovascular Disease · Torrington, CTNPI 1003996240

Payments from drug & device makers

$1,816in general payments, 2019–2025

Across 85 payments — averaging $21.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$948
  • E.r. Squibb & Sons, L.L.C.$283
  • Pfizer$231
  • Amgen$93
  • Sanofi-aventis U.S. LLC$46
  • Johnson & Johnson$38
  • plus $177 from 8 others

What the payments were for

  • Food & beverage$1,816100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,816 in reported general payments places this provider in the 50th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$95,583
Medicare patients
952
Services billed
2,473

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban119$136,682
EntrestoSacubitril/Valsartan36$27,478
XareltoRivaroxaban18$19,939
JardianceEmpagliflozin11$12,648
Diltiazem 24hr Er (Cd)Diltiazem Hcl31$1,281
Metoprolol Succinate106$887
Rosuvastatin Calcium77$813
Atorvastatin Calcium94$810
Midodrine Hcl16$608
Irbesartan55$585
Metoprolol Tartrate58$421
Carvedilol65$359
Ezetimibe13$356
Digoxin11$354
Losartan Potassium49$347

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$231$136,682119 claims
NovartisEntresto$20$27,47836 claims
Johnson & JohnsonXarelto$38$19,93918 claims
Boehringer IngelheimJardiance$22$12,64811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 415 cardiovascular disease providers in Connecticut.

Other cardiovascular disease in Torrington

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →